According to post hoc analysis, SG can improve the prognosis of HR+/HER2- patients regardless of Trop-2 expression levels, providing a new treatment option for more HR + HER2- metastatic breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.